Skip to main content

Main menu

  • Home
  • COVID-19
    • Articles & podcasts
    • Blog posts
    • Collection
    • News
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
    • Career Ad Discount
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2021
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • COVID-19
    • Articles & podcasts
    • Blog posts
    • Collection
    • News
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
    • Career Ad Discount
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2021
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
News

Appointment of Pfizer executive to CIHR stirs controversy

Ann Silversides
CMAJ November 24, 2009 181 (11) E256-E257; DOI: https://doi.org/10.1503/cmaj.109-3085
Ann Silversides
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Metrics
  • Responses
  • PDF
Loading

The appointment of a senior executive from pharmaceutical giant Pfizer Canada to the governing council of the Canadian Institutes of Health Research (CIHR) has raised concern among some physicians about industry influence at the granting council.

It’s a conflict of interest to appoint Dr. Bernard Prigent, vice-president and medical director of Pfizer Canada, to the CIHR council, suggests Dr. Sidney Wolfe, director of the health research group at the Washington, DC-based watchdog organization Public Citizen.

The pharmaceutical industry is a strong advocate for boosting funding for research organizations because basic research supported by public money at universities is often the source of discoveries that are later taken up and commercialized by industry, Wolfe says. Prigent’s appointment places an industry representative “directly at the policy-making level and it is not unlikely that someone from Pfizer will recommend things in favour of the drug industry.”

Federal Health Minister Leona Aglukkaq earlier this month made Prigent the first pharmaceutical company representative on CIHR’s governing council.

The council is responsible for developing CIHR’s “strategic directions, goals and policies,” approving the budget, appointing scientific directors, creating and terminating institutes and evaluating the organization’s performance. CIHR media relations officer David Coulombe says appointments to the 17-member body are made by the federal cabinet, although CIHR’s president may advise the health minister on appropriate candidates.

CIHR president Dr. Alain Beaudet told delegates to the 7th Clinical Trial in Canada conference in Toronto, Ontario, on Oct. 19 that the agency hopes to synchronize its activities with the federal government’s overall science and technology strategy, Mobilizing Science and Technology to Canada’s Advantage. “We also want to ensure closer ties with industry, that they sit at the same table at the precompetitive level. We want to help industry to succeed and encourage them to invest,” Beaudet said.

Figure1
  • Download figure
  • Open in new tab
  • Download powerpoint

Pfizer Canada Vice-President and Medical Director Dr. Bernard Prigent is the first pharmaceutical company representative to be appointed to the governing council of the Canadian Institutes of Health Research. Image courtesy of Pfizer Canada

Wolfe notes that while Canada has appointed Prigent to CIHR’s governing council, conflict-of-interest policies have been tightened considerably at the United States National Institutes of Health (NIH).

There are currently no industry representatives on the NIH Advisory Committee to the Director, though there have been such members in the past, spokesman Don Ralbovsky stated in an email. “There’s nothing in the legislation, or in the Advisory Committee to the Director charter, that prohibits an individual employed at a pharmaceutical or other private firm from serving on a federally chartered committee. However, NIH is aware of the need to be diligent in reviewing meeting agendas for the purpose of conflict of interest and member employment, regardless of whether the member is from industry, academe, government or other entity. All financial information is reviewed very carefully at the service center and the NIH Ethics Office.”

Potentially, industry representation on a governing council could skew grant selection, says Dr. Joel Lexchin, a professor at the School of Health Policy and Management at York University in Toronto, Ontario. Lexchin is uncomfortable with Prigent’s appointment “because the priorities of the private sector are not necessarily the same as those of the public sector.”

For example, debate now revolves around whether publicly funded research should be exclusively licensed to industry or made more widely available through nonexclusive licenses in order to benefit nonprofit groups and facilitate access to products in the developing world, Lexchin says. Meanwhile, the appointment is symptomatic of CIHR placing greater emphasis on public–private research partnerships “and when researchers have to raise money from industry, it means they may skew their priorities to align themselves with what industry is interested in, in order to get grants.”

Others say that as long as Prigent isn’t directly involved in grant selection, and is confined to broader “policy” discussion, there shouldn’t be a problem.

If a governing council has a clear mandate, robust leadership and represents the public interest, it’s preferable that “industry had a place” at a relatively transparent table than at “less well-defined meetings between the CIHR board and ‘representatives’ of industry where they may be a greater potential for influence,” Dr. David Henry, president of the Institute of Clinical Evaluative Sciences in Toronto, Ontario writes in an email.

Bryn Williams-Jones, assistant professor of bioethics at the University of Montréal’s faculty of medicine, says Prigent’s appointment may not represent a direct conflict of interest, but it raises the issue of the “vision for a funding council.”

“Many of us are critical of the move in CIHR and the SSHRC (Social Sciences and Humanities Research Council) towards the increasing importance of commercialization,” he says.

The federal government views universities as “knowledge factories and economic engines,” Williams-Jones adds. But governments have a bad track record when they intervene in basic research, which often yields the greatest economic and sociietal benefits. “The reason they give out Nobel prizes 40 years later is because that is when a discovery [in basic science] has an impact.”

Footnotes

  • Published at www.cmaj.ca on Oct. 20

PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 181 (11)
CMAJ
Vol. 181, Issue 11
24 Nov 2009
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Appointment of Pfizer executive to CIHR stirs controversy
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Appointment of Pfizer executive to CIHR stirs controversy
Ann Silversides
CMAJ Nov 2009, 181 (11) E256-E257; DOI: 10.1503/cmaj.109-3085

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Appointment of Pfizer executive to CIHR stirs controversy
Ann Silversides
CMAJ Nov 2009, 181 (11) E256-E257; DOI: 10.1503/cmaj.109-3085
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Footnotes
  • Figures & Tables
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Concepts of bias and appointments to the Governing Council of the Canadian Institutes of Health Research
  • CIHR appointment
  • CIHR and Prigent
  • Google Scholar

More in this TOC Section

  • Time to embrace Dr. Google?
  • Hospitals grappling with nurse exodus
  • How can medicine close its gender pay gap?
Show more News

Similar Articles

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions

Copyright 2021, CMA Joule Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of the resources on this site in an accessible format, please contact us at cmajgroup@cmaj.ca.

Powered by HighWire